TMEM165

Across TCGA pan-cancer cohorts, TMEM165 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM165 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMEM165 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM165 expression acts as an unfavorable survival marker.

LUAD, LIHC, and PRAD are the cancer types where TMEM165 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.342	0.893	<.001	12	view →
LIHC	OS	Median	All	0.152	0.688	.017	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMEM165–LUAD (DFS)

Open the LUAD breakdown →